Platinum therapy resistance is associated with an enrichment of tumour angiogenesis in epithelial ovarian cancer
The clinical and pre-clinical data discussed has potentially significant clinical implications in the management of treatment-relapsed HGSOC.
Platinum-resistance in relapsed HGSOC is an indicator for response to antiangiogenic agents.
The novel identification of chemotherapy-mediated selection for an angiogenic phenotype in EOC, through upregulation of the PDGFR-VEGF-A signaling pathway.
Targeted inhibition of PDGFR (using TKI or siRNA knockdown) reverses platinum therapy resistance in EOC.
This clinical and pre-clinical data supports the use of anti-angiogenic agents in the first and second line setting in patients with innate and acquired resistance to platinum therapy, respectively.
